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CTL epitope (KSPWFTTL) encoded by AKV/MCF type
Murine leukemiaviruses (MuLV) areoncogenic retrovi-of murine leukemia virus (MuLV) differs from the se-
ruses inducing lymphomas in mice, and occur in two
quence in Friend/Moloney/Rauscher (FMR) type in one
major types: endogenous AKV/MCF-type MuLV and
residue (RSPWFTTL). CTL experiments indicated de-
exogenous Friend/Moloney/Rauscher (FMR)-type of
fective processing of the FMR peptide in tumor cells. MuLV. T cell immunity plays an important role in protec-
Proteasome-mediated digestion of AKV/MCF-type 26- tion against these viruses, as shown by several investi-
mer peptides resulted in the early generation and gators (reviewed by Zijlstra and Melief, 1986). CTLs
higher levels of epitope-containing fragments than di- raised against MuLV in H-2b mice are either specific for
gestion of FMR-type peptides, explained by prominent the AKV/MCF type or for FMR type of MuLV (Plata and
cleavage next to R in the FMR sequence. The frag- Lilly, 1979). Indeed, our MCF virus-specific CTL clones
ments were identified as 10- and 11-mer peptides and are not able to recognize tumor cells expressing FMR
wereefficiently translocated by TAP.The naturally pre- type of MuLV (Sijts et al., 1994a). We have identified
sented AKV/MCF peptide is the 8-mer, indicating ER the MCF-encoded immunodominant CTL epitope MCF8
peptide trimming. In conclusion, a single residue ex- (KSPWFTTL) (Sijts et al., 1994a) that was also immuno-
change can cause CTL epitope destruction by specific dominant in AKR/Gross MuLV (White et al., 1994). This
proteasomal cleavage. epitope differs in only 1 aa from the homologous se-
quence in FMR-type viruses, which have an arginine (R)
Introduction instead of a lysine (K) at position 1 of the epitope. This
does not affect peptide binding to MHC class I Kb mole-
Cytotoxic T lymphocytes (CTLs) recognize endoge- cules (Sijts et al., 1994a). Peptide vaccination showed
nously derived antigenic peptides presented by major that the FMR peptide is immunogenic in C57BL mice
histocompatibility complex (MHC) class I molecules. (Sijts et al., 1994a). However, CTLs raised against the
The proteasome complex plays an important role in the FMR type of peptide were not capable of recognizing
generation of MHC class I–presented peptides (re- the tumor cells endogenously expressing FMR, whereas
viewed byGoldberg and Rock, 1992; Howard and Seelig, CTL raised against both the MCF/AKV and FMR pep-
1993). Processing of endogenous protein antigens re- tides were able to recognize MCF-induced tumor cells.
This suggested that the epitope is not processed inquires targeting to the proteasome complex, in which
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FMR-type MuLV. We now address the question whether
the difference in amino acid sequence between both
types of viruses, either in the epitope itself or in the
flanking regions, can influence processing and transport
of the epitope. We have used purified 20S proteasomes
to perform digestion analysis of 26-mer synthetic pep-
tides, covering the CTL epitope in either AKV/MCF or
FMR context. These experiments show that epitope
containing fragments are generated from peptides en-
coding the AKV/MCF sequence, but inefficiently from
the FMR sequence. We describe that in the FMR type
of MuLV this epitope is destroyed by the presence of a
dominant protease cleavage site within the epitope. This
shows that a single amino acid change can abolish pro-
ductive processing of an immunodominant CTL epitope.
Results
MuLV-Type Specific CTLs Suggest Figure 1. Amino Acid Sequences of the MuLV CTL Epitope-Encod-
Defective Processing ing Region of env–p15E
CTLs raised against AKV/MCF MuLV are not cross-reac- (A) PCR analysis was performed on cDNA derived from total RNA
tivewith FMR MuLV (Plata and Lilly, 1979). We generated of MuLV-induced cell lines 771 (MCF1233) and RMA (Rauscher
MuLV), as present in our lab. Sequencing of the PCR fragmentsCTL against an MCF virus, derived from C57BL mice
revealed that both nucleotide and amino acid sequences were iden-(MCF1233) (Zijlstra et al., 1983). These CTLs recognize
tical to those published for both virus types. Amino acid sequencesa Kb-presented epitope KSPWFTTL (M8) present in the
of both 771 and RMA are aligned and differences are depicted in
p15E–env gene product (Sijts et al., 1994a). The corre- bold. Nucleotide sequences corresponding to the CTL epitope are
sponding sequence in FMR type of MuLV differs in only 1 shown.
aaat position 1: RSPWFTTL(FMR8). CTLs raised against (B) 26-mer synthetic peptides used for proteasome digestion analy-
sis. Four peptides were used: two wild-type peptides (FMR wt; MCFboth M8 and FMR8 synthetic peptides were able to
wt), and two peptides with one residue changed for the respec-recognize tumor cells (771 lymphoma) endogenously
tive amino acid of the other virus type at position 4 (FMR mut;expressing MCF1233 MuLV, but not RMA tumor cells
MCF mut).
expressing the FMR-type Rauscher MuLV (Sijts et al.,
1994a). In this study, we have used a 771-directed CTL
clone A9 that was selected to recognize FMR8 synthetic using primers surrounding a fragment of 324 bp. Se-
peptide next to the M8 peptide. Despite cross-reactivity quencing of these fragments resulted in completely
at the synthetic peptide level, clone A9 was not able to identical nucleotide as well as amino acid sequences
recognize RMA or RBL-5 cells endogenously expressing as published, including the six type-specific residues
Rauscher MuLV, indicating absence of presentation of (Figure 1A).
the FMR peptide. Expression of Kb MHC class I and of
the MuLV p15E protein on RMA cells, as detected with No Generation of Antigenic Peptides
specific monoclonal antibodies, was found normal (data by Proteasomal Digestion
not shown). In addition, RMA cells can be recognized by of FMR MuLV Sequences
Moloney MuLV-specific CTLs recognizing an env–gp70 To explore whether the lack of presentation of the FMR8
encoded Kb-binding peptide (Sijts et al., 1994b), indicat- peptide is due to a processing defect determined by
ing normal expression of MuLV-encoded proteins. the amino acid sequence, 26-mer synthetic peptides
These data suggest that this MuLV CTL epitope is not covering the epitope and residues of interest in close
correctly processed in the FMR type of MuLV. proximity to the epitope were synthesized (Figure 1B).
Both the natural and specifically changed MCF/AKV and
FMR type of peptides were used for in vitro digestionSequence Analysis of Epitope-Containing Region
The lack of presentation of the peptide in FMR MuLV– experiments using isolated 20S proteasomes. Solubility
problems prohibited the use of C-terminal elongatedinduced tumor cells prompted us to compare the amino
acid sequence of the region in proximity of the epitope. peptides. These cover the transmembrane region of
p15E and thereby contain an extensive stretch of hy-The published sequences of Moloney MuLV (Shinnick
et al., 1981) and MCF1233 MuLV (Sijts et al., 1994c) drophobic residues.
20S proteasomes were isolated from RMA cells. Fig-revealed next to the R to K difference within the epitope
two divergent residues upstream (at positions 210 and ure 2 shows a two-dimensional polyacrylamide gel indi-
cating that all identifiable proteasomal protein compo-218 away from the epitope) and three divergent resi-
dues downstream (positions 110, 113, and 1 29) of nents are present. The N-terminally flanked peptides
were incubated with isolated 20S proteasomes for 24 hrthe epitope (Figure 1A). To exclude the possibility of
additional mutations in the RMA and 771 cell lines pres- at 378C or were mock incubated (without proteasome).
Cytotoxicity assays were performed to test the genera-ent in our lab, we performed RT–PCR analysis of cDNA
generated from isolated RNA of these two cell lines, tion of fragments with antigenic potency in the peptide
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Figure 2. Analysis of 20S Proteasomes Iso-
lated from RMA Cells by Two-Dimensional
Gel Electrophoresis
The subunits of highly purified RMA protea-
somes (50 mg) were separated on NEPHGE/
PAGE gels as described (Groettrup et al.,
1995) and visualized by Coomassie stain.
Each of the visible protein spots can be as-
signed to one of the 16 subunits of the mouse
proteasome according to their migratory po-
sitions (M. G., unpublished microsequence
data). For simplicity, we only marked the four
exchangeable subunits LMP2, LMP7, d, and
MB-1. Molecular masses are given in kilo-
daltons.
digests. Kb expressing RBL-5 target cells were loaded
with titrated concentrations of 20S proteasome-
digested peptides, and tested for recognition by CTL
clone A9. Figure 3A shows strong lysis of RBL-5 cells
loaded with proteasome-digested K-containing pep-
tides in comparison with mock-treated peptides, indi-
cating the generation of epitope-containing fragments.
In contrast, target cells loaded with proteasome-
digested R-containing peptides were not susceptible to
lysis (Figure 3B). CTL clone A9 was able to recognize
both synthetic 8-mer peptides, including the relevant
10- and 11-mer natural length variants (see below) (Fig-
ures 3C and 3D).
These results suggest that proteasomal activity in
vitro correlates with antigen presentation in vivo.
Proteasomal Digestion Destroys Epitope
in FMR MuLV Type
The proteasomal digestion products were analyzed by
reverse-phase high performance liquid chromatography
(RP–HPLC) and online mass Spectrometry. Figure 4
shows a typical experiment, comparing wild-type FMR
(A) and wild-type MCF (B) 24 hr digests. Detectable
degradation products (15–20 different fragments, de-
pending on theexperiment) were identified by their mass
and subsequent sequencing. The abundantly occurring
fragments and those relevant for epitope generation are
Figure 3. Sensitization of RBL-5 Target Cells with 20S Proteasomeshown. When we evaluated the presence of the optimal
Digestion Products of Synthetic Peptides, as Recognized by CTL8-mer epitope, this fragment was not detectable ineither
Clone A9 in a 51Cr Release AssayMuLV-type digest (Figure 4, top row). The C-terminal
26-mer synthetic peptides were digested with purified 20S protea-fragment ISTIM was generated from both sequences
somes in vitro as described. Digestion products were titrated in(Figure 4, row 2). A 14-mer N-terminal fragment was
2-fold dilution steps and preincubated with labeled target cells. (A
predominantly present indigests of the FMR type(Figure and B) depict the equivalent of the initial concentration of the 26-
4, row 5), indicating a cleavage site after R. Notably, mer substrate peptide (nM eq). (C and D) depict the actual concen-
trations of the added synthetic peptides.two epitope-containing fragments (a 10-mer and an 11-
(A) MCF-derived peptides MCF wt (squares) and MCF mut (circles),mer) were present in the MCF-type digest, but in signifi-
either incubated with proteasomes (closed symbols) or mock (with-cantly lower amounts in digests of the FMR type of
out proteasomes) incubated (open symbols).peptides (rows 3 and 4). To confirm peptide degradation
(B) FMR-derived peptides FMR wt (circles) and FMR mut (squares),
as a proteasomal function, the proteolysis was carried either incubated with proteasomes (closed symbols) or mock (with-
out in the presence of inhibitors. Peptide aldehyde inhib- out proteasomes) incubated (open symbols).
(C) Cytotoxicity of clone A9 on RBL-5 target cells sensitized withitors selectively block proteasome activity in vitro and
serial dilutions of synthetic peptides MCF8 (KSPWFTTL, open cir-in vivo (Rock et al., 1994). Both LLnL and MG132 peptide
cle), MCF10 (FNKSPWFTTL, open square) and MCF11 (FNKSPWFTaldehydes were able to inhibit the generation of the
TLI, open triangle).relevant fragments in a dose-dependent manner (data
(D) Cytotoxicity of clone A9 on RBL-5 target cells sensitized with
not shown). serial dilutions of synthetic peptides FMR8 (RSPWFTTL, closed cir-
Next to the K to R difference we also introduced a Q cle), FMR10 (FNRSPWFTTL, closed square) and FMR11 (FNRSPWF
TTLI, closed triangle).to T mutation in the synthetic peptides as present in the
Immunity
118
Figure 4. Biochemical Analysis of Proteasome Digestion Products Using HPLC Mass Spectrometry
Depicted is the presence of the most frequently occurring fragments by the ion current of the specific masses in 24 hr digests of FMR wt (A)
and MCF wt (B) peptides. Row 6 shows the total ion current profile of all digestion products as separated by HPLC.
respective viral sequence (see Figure 1). Quantification fragments were undetectable at 1 hr and both 10- and
11-mer peptides occurred later and reached signifi-of epitope-containing fragments was performed using
standardization with the respective synthetic peptides cantly lower levels. The difference between both MuLV
types is most prominent at early timepoints. The most(data not shown). The generation of these fragments
after 24 hr of digestion was predominantly found in di- dominant peptide derived from the FMR sequence was
the 14-mer peptide without antigenicity, abundantlygests of the MCF-type peptides (5 to 10-fold higher than
in FMR digests), irrelevant of the Q to T mutation at present already after 1 hr, suggesting early degradation
of the potential epitope. In digests of the MCF 26-merresidue 3 of the peptide.
From these results, the major protease cleavage sites peptide, the 14-mer was barely detectable after 2 hr
and remained far below the level of FMR after 4 hr ofcan be deduced as indicated by bold arrows on the top
of Figure 4. The proteasome cleaves dominantly after digestion. Thus, the different propensity of the two pep-
tides to be cleaved into antigenic peptide precursorsthe leucine at position 11, after the leucine at position
21, and after the isoleucine at position 22. The most was also apparent after short-term degradation.
striking difference between the R-containing peptides
and the K-containing peptides is the protease cleavage Epitope-Containing Peptides as Generated
by Proteasomal Digestion Are Efficientlysite after the arginine at position 14. This indicates that
an important protease cleavage site within a potential Translocated by TAP
In a previous study (Neisig et al., 1995), the MCF8 epi-CTL epitope is responsible for destruction of the FMR8
but not the M8 epitope. tope was shown to be inefficiently transported by TAP
in permeabilized RMA cells. However, when the 8-mer
epitope was elongated with its natural flanking resi-Kinetics of the Epitope-Containing
Fragment Processing dues, TAP-mediated translocation was dramatically im-
proved. To a greater or smaller extent, 9 and 10-merDigestion of synthetic peptides for the relatively long
period of 24 hr in the constant presence of proteasome elongated peptides were translocated (also shown in
Table 1). In this study, we found two epitope-containingis an artificial situation. If the observed difference repre-
sents a biologically relevant phenomenon, the genera- fragments generated by in vitro 20S proteasome diges-
tion from 26-mer peptides. We tested the capacity oftion of antigenic peptides from the MCF sequence
should occur earlier. The kinetics of the generation of these peptides to be translocated by TAP. Both the
10-mer FNKSPWFTTL and 11-mer FNKSPWFTTLI wereantigenic peptides was investigated by mass spectro-
metric analysis of aliquots of the digestion mixture at made synthetically and subjected to theTAP-dependent
translocation assay (Table 1). The 10-mer and 11-merearly timepoints. As indicated in Figure 5, the epitope-
containing MCF fragments were detectable as early as peptides of both the AKV/MCF type as well as the (hypo-
thetical) FMR type were translocated efficiently.1 hr and steadily accumulated. The homologous FMR
Proteasome-Mediated Viral CTL Epitope Processing
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Figure 5. Time Course of the Generation of
Epitope-Containing Fragments from the MCF
and FMR 26-mer by the 20S Proteasome
Aliquots from different timepoints were ana-
lyzed by mass spectrometry. This graph
shows the relative amounts of the epitope-
containing fragments, 10-mer (FNXSPWF
TTL), 11-mer (FNXSPWFTTLI), and the N-ter-
minal 14-mer (FESXQGWFEGLFNX), pro-
duced after 1 hr, 2 hr, and 4 hr of incubation,
respectively. X stands for the amino acid resi-
due Q and K in the MCF sequence or T and
R in the FMR sequence.
These results indicate that the 20S proteasomegener- tested all synthetic length variant peptides in an RMA-S
MHC class I binding assay. The peptide transporter–ates fragments that can be efficiently translocated into
the ER without further processing. deficient cell line RMA-S can be loaded with exogenous
peptides, thereby stabilizing the MHC class I molecules
that were up-regulated for expression at 268C. Kb ex-Identification of the Naturally Presented
Peptide Epitope pression was detected using a specific monoclonal anti-
body and the fluorescence is depicted in Figure 6. TheOur previous studies (Sijts et al., 1994a) strongly indi-
cated that the 8-mer peptide, with a so-called classic data show that the AKV/MCF 8-mer peptide is the
strongest binding peptide. Even at low peptide concen-Kb binding motif, was the naturally presented peptide.
Bycomparison of synthetic length variants, it was shown trations, it shows similar binding affinity as a control
9-mer Sendai virus CTL epitope S9 (Figure 6A). The 10-that the 8-mer was the optimally binding and recognized
peptide. In the present study, we found that the protea- and 11-mer, but also both 9-mer variants (NKSPWFTTL
and KSPWFTTLI) and the 7-mer (SPWFTTL) are poorlysome generates longer (10- and 11-mer) peptides than
the 8-mer and even that TAP efficiently translocates the binding peptides. The FMR peptide binding study (Fig-
ure 6B) shows comparable results, and confirms thatlonger peptides rather than the 8-mer. This raises the
question of what is actually presented in the Kb molecule the difference between the two virus types is not due
to differential MHC binding capacity.at the cellular membrane. Making use of the knowledge
that the 10- and 11-mers most likely enter the ER, we To identify the naturally presented peptide, 771 cells
and RMA cells were treated at low pH to elute MHC-
bound peptides and the eluate was subjected to HPLC
Table 1. TAP-Dependent Translocation of M8 and FMR8
separation. The individual fractions were incubated withPeptides with Natural Flanking Residues in Streptolysin
target cells and tested for recognition by clone A9 in aO–Permeabilized RMA Cells
cytoxicity assay. Figure 7 shows that only fraction 17
Competitor IC50 (mM) of the 771 eluate was recognized by the CTL, indicating
M8 .100 the presence of the natural peptide. The RMA-derived
FMR8 .100 fractions were not recognized, again showing that the
N-M8 .100 FMR peptide is not detectably presented. Coelution of
M8-I 20 the synthetic peptide variants indicated that only the
M8-IS .100 8-mer synthetic peptide elutes in fraction 17, whereas
N-M8-I 2
the related synthetic length variants elute in different
Peptides identified by proteasomal digestion fractions, as indicated with arrows. These findings
FN-M8a 3
prompted us to conclude that the peptide precursorsFN-FMR8 3
resulting from proteasomal digestion are trimmed in theFN-M8-I 6
ER after translocation.FN-FMR8-I 4
Competition experiments were performed using a radiolabeled
model peptide as described (Neisig et al., 1995). The IC50 value was
Discussioncalculated for each competing peptide based on titration curves,
and is defined as the concentration of competitor peptide at which
50% inhibition of translocation of the model peptide is reached. In this study, we report the differential processing of a
a Owing to a synthesis error, thispeptide has been abusivelyannoted CTL epitope sequence from two related naturally oc-
to an IC50 . 100 mM in a previous report (Neisig et al., 1995). curring MuLV types. The peptide in these two virus types
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11-mer precursors are only detectable after extended
times of degradation. Whether cleavage products that
occur only after long-term degradation in vitro are gener-
ated at all in vivo remains open, considering the fact
that proteasomes are probably constantly recharged
with new polypeptides.
Proteasome digestion of synthetic peptides covering
the AKV/MCF region generates 10- and 11-mer epitopes
containing peptide fragments, which are, in addition,
selected by the TAP transporter. Longer precursor pep-
tides were generated by the proteasome, indicating the
importance of flanking regions. Thus, the proteasome
can directly generate peptide fragments that are optimal
molecules to be recognized and translocated by the
transporter complex. Indeed, modified flanking can in-
crease the generation of antigenic peptides (Del Val et
al., 1991; Eggers et al., 1995). For MCF8 epitope presen-
tation, longer precursor peptides are essential, since
the minimal 8-mer peptide is not transported by TAP
(Neisig et al., 1995). Longer precursor peptides suggest
additional N-terminal trimming of the epitope. Our data
suggest that additional trimming of the 10/11-mer pep-
tide takes place in the ER compartment. Evidence for
the occurrence of peptide trimming in the ER has been
obtained by others (Roelse et al., 1994; Snyder et al.,
1994; Elliot et al., 1995: Hughes et al., 1996). Trimming
seems to take place primarily N-terminally, which fits for
the MCF8 precursors representing mainly N-terminally
elongated peptides.
Peptide binding studies performed using the RMA-S
MHC class I stabilization assay strongly suggest that
the 8-mer peptide is the optimal Kb-binding peptide.
Figure 6. The 8-mer Peptide Is the Optimal Kb Binding Peptide Both 10- and 11-mer peptides poorly stabilized the MHC
RMA-S peptide binding assay to compare the relative binding ca- complex. However, the CTL assay (Figures 3C and 3D)
pacity of all possible length variants of the MCF (A) and FMR (B) shows comparable recognition of the 10-mer and 8-mer.
peptide sequence of the naturally presented epitope. High mean Although both assays are based on different principles
fluorescence values indicate high levels of cell surface expressed
that might explain the contrasting outcome, e.g., degra-MHC class I Kb molecules as stabilized by the added peptide. High
dation of 10-mers to 8-mers during the cytotoxicityaffinity binding peptides can stabilize class I molecules even at
relatively low concentrations of peptide. assay, an alternative explanation might be differential
(A) S9 (FAPGNYPAL) is a Sendai virus CTL epitope Kb-binding control Kb–peptide complex dissociation. We found that disso-
peptide. M7 (SPWFTTL) is a 7-mer peptide expected to be generated ciation rate is a good predictive value for potential CTL
by proteasomal degradation of the FMR sequence. Length variants
epitopes (Van der Burg et al., 1996). We have determinedof MCF8 (M8), (KSPWFTTL); M9.1, (NKSPWFTTL); M9.2, (KSPWFT
the offrate of the relevant length variants of the epitopeTLI); MCF10 (M10), (FNKSPWFTTL); and MCF11 (M11), (FNKSPWFT
by loadingRMA-S cells with high concentrations of pep-TLI).
(B) A10 (SGPSNTPPEI) is an Adeno virus type 5 CTL epitope Db- tide and measuring the dissociation kinetics at 378C
binding control peptide. Length variants of the FMR8 (RSPWFTTL) by specific MAb (data not shown). The 10-mer peptide
are identical as for the MCF8 except they contain an R instead slowly dissociates from the Kb complex, similar to the
of a K. 8-mer peptide. In contrast, the 11-mer peptide rapidly
dissociates, most likely because the additional isoleu-
only differs at a single amino acid, the closely sur- cine disturbs the proper fit of the leucine anchor residue
rounding sequences are almost identical, and no differ- in its pocket of the Kb groove.
ence in binding affinity for the class I Kb-binding groove The routing of transmembrane molecules like p15E–
has been found. Both optimally binding peptides are env proteins before targeting to the 20S proteasome in
poorly transported by TAP. However, if they are elon- the cytosol is not known. However, the TAP dependence
gated N-terminally, their transport is equally improved. of processing of this transmembrane molecule suggests
The only difference found in this system is the cleavage that the protein is cytosolically degraded and its frag-
specificity of the 20S proteasome in vitro. In digests of ments translocated by TAP, similar to what has been
the FMR substrate, the first cleavage product that can observed for measles virus fusion protein (Van Binnen-
be detected is the 14-mer FESTQGWFEGLFNR gener- dijk et al., 1992). How this is achieved is unclear, but
ated by a cleavage product that destroys the antigenic recent data indicate translocation mechanisms of ER
epitope. In contrast, the first cleavage products of the proteins into the cytosol (Wiertz et al., 1996).
MCF-type sequence are a 10-mer (FNKSPWFTTL) and From our AKV-related model virus MCF1233 (Zijlstra
an 11-mer (FNKSPWFTTLI) containing the optimal epi- et al., 1983; Sijts et al., 1994c), we have gained insight
in the immune response against MCF1233-induced Ttope sequence. In the FMR digest, likewise, the 10- and
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Figure 7. The MCF 8-mer Peptide Is the Nat-
urally Presented Peptide
Acid elution of naturally presented peptides
from 771 (A) and RMA (B) cells. Of both cell
lines, 109 cells were 0.1% TFA eluted and the
low molecular mass fraction was subjected
to HPLC chromatography, resulting in 38
fractions. All fractions were incubated with
target cells and tested for recognition by CTL
clone A9. Coelution of the synthetic length
variants in the respective fractions is indi-
cated by arrows.
and B cell lymphomas of different MHC backgrounds at the proteasome level, precluding further processing
and presentation. Niedermann et al. (1995) compared(Vasmel et al., 1988). By immunization with an MCF1233-
induced B cell lymphoma in C57BL/10 mice, we were two independent CTL epitopes of chicken ovalbumin,
using Edman degradation to analyze the proteasomalable to isolate specific CTL lines and clones and we
have identified the MCF1233-encoded CTL epitope M8 digestion products. In their case, the 8-mer immuno-
dominant epitope appeared to be exactly cleaved from(KSPWFTTL) (Sijts et al., 1994a). Early studies in the
MuLV field already showed that CTLs apparently have its surrounding sequences. In addition, a number of pro-
teasomal cleavage sites were found within a subdomi-fine specificity for the two main types of MuLV, the AKV/
MCF and FMR types (Plata and Lilly, 1979). In general, nant ovalbumin CTL epitope, which could explain the
subdominance of the epitope.no cross-reactivity is found when CTLs are raised
against one type or the other in the H-2b haplotype. The We demonstrate,using online mass spectrometry and
sequencing, that one crucial cleavage site apparentlyidentification of MuLV CTL epitopes helped inexplaining
this selectivity (Sijts et al., 1994a, 1994b). The AKV/MCF defines the antigenicity of the sequence. Thus, differ-
ences in the sequence of naturally occurring viruses canpeptide sequence differed in one residue (K to R) from
the FMR sequence. The lack of presentation of this epi- determine the presence or absence of an immunodomi-
nant CTL epitope, not only at the level of binding totope might be explained at several levels. We tested
expression levels of MHC class I and p15E–env viral MHC or T cell receptor (TCR), but also at the processing
level by formation of a proteolytic site. Although theproteins, binding capacity of the peptide to Kb mole-
cules, and the in vivo presence of CTLs capable of rec- nucleotide difference of the K (AAG) to R (AGA) ex-
change in the two MuLV types involves two nucleotides,ognizing the peptide. None of these parameters could
explain the observation. Here, we show that the pres- theoretically only one (A to G) nucleotide change (K is
AAA or AAG; R is AGA or AGG) can lead to the formationence of an R in this sequence leadsto selective degrada-
tion of the potential CTL epitope in FMR viruses already of this proteolytic site.
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serum (CTL), penicillin (100 IU/ml) and 20 mM 2-mercaptoethanol.Viral immune escape mechanisms have been sug-
T cell clones were cultured in the presence of 20 IU/ml hIL-2.gested to occur at various levels as reviewed by Melief
(1992), including down-regulation of MHC, down-regula-
Cytotoxicity Assaystion of antigen, and secretion of immunosuppressive
CTL assays were performed as described (Sijts et al., 1994a). In
factors. Specific mutations in T cell epitopes can result short, 2 3 103 Na251CrO4-labeled target cells were incubated with
in either nonbinding to MHC (anchor replacement) or effector cells for 5–6 hr at 378C. The culture supernatant was har-
nonrecognition by the TCR (interaction residue replace- vested and counted for released radioactivity. The percentage of
specific 51Cr-release was calculated as a ratio of 100 3 (cpm experi-ment). Here, we demonstrate a new potential immune
mental release 2 cpm spontaneous release): (cpm maximal releaseevasion mechanism; namely, the potential of generating
(1% Triton X-100) 2 cpm spontaneous release). All assays werea proteasomalcleavage site within the epitope.Frequent
carried out in triplicate. For target cell sensitization, 51Cr-labeled
amino acid changes have been observed in CTL epi- target cells were incubated with peptide or proteasomal digests of
topes in HIV gag (Phillips et al., 1991) and EBV EBNA peptides in concentrations indicated, 1 hr prior to addition of the
(De Campos-Lima et al., 1994). These have been sug- CTL. Peptides remained present during the assay.
gested to represent immune escape variants, only some
Peptidesof which are clearly MHC nonbinding peptides. Two EBV
Peptides were synthesized on a multiple peptide synthesizer (Ab-EBNA4 CTL epitope mutations (V to L; K to R) did not
imed AMS 422) as described (Gausepohl et al., 1990). Peptidesaffect binding to HLA-A11, and CTLs recognized the
were analyzed for purity by RP–HPLC, lyophilized, and dissolved inmutant peptide but not cells expressing the mutated
phosphate-buffered saline. Stock solutions of 5 mg/ml were stored
EBNA4 protein endogenously (De Campos-Lima et al., at 2808C. The MCF peptide for the kinetic study was synthesized
1994). These findings could indicate a defect at the pro- on a ABI-synthesizer 433A.
cessing level. Also, in the MuLV model, the possibility
exists that the single residue difference between AKV/ PCR Analysis
RT–PCR analysis was performed as described (Hawes et al., 1993).MCF and FMR MuLV has been selected for by immune
Total RNA was isolated from 771 and RMA tumor cell lines usingpressure. Our MCF1233 MuLV has been isolated from
the RNAzol method (Cinna Biotecx) and cDNA was generated usingB10.A (H-2a) mice expressing Kk, indicating a lack of
AMV reverse transcriptase (Promega). Oligonucleotide primers were
pressure on Kb-presented peptides. On the other hand, selected up- and downstream of the M8 CTL epitope, based on
tumor cell lines like RBL-5, expressing FMR type of the sequence of MCF 1233 (Sijts et al., 1995) and Rauscher MuLV
MuLV, have been maintained by serial in vivo passage (Shinnick et al., 1981).
in H-2b-expressing mouse strains (C57BL/6) in the past MCF 59 primer (7201–7225): GCC ACT CAG CAG TTC CAA CAA
CTC C(Plata and Lilly, 1979) that might have resulted in selec-
MCF 39 primer (7687–7711): ATT CAC GCG ATT CTA CTT CTTtive pressure on class I (Kb and Db)–presented CTL epi-
CTG Gtopes.
Rauscher 59 primer (7348–7371): AAA GAA GGA GGA CTG TGT
MHC class I binding motifs (Falk et al., 1991) have GCT GCC
enabled us to predict potential CTL epitopes within a Rauscher 39 primer (7648–7672): GCT GGT GGT ATT GTT GAG
given sequence. Indeed, we have identified CTL epi- TCA GGA C
topes by screening all motif-based class I–binding pep- PCR fragments after 40 cycles were cloned and sequenced using
the Circumvent Kit (Circumvent Thermal Cycle Dideoxy DNA se-tides with tumor-specific CTL (Sijts et al., 1994a, 1994b).
quencing with VentR (exo2) DNA polymerase; New England Biolabs,However, it is still difficult to select further the immuno-
Incorporated).logically relevant CTL epitopes among high affinity MHC
class I–binding peptides, since the rules for processing
Proteasome Digestion Assays
of T cell epitopes are poorly understood. This report 20S proteasomes were isolated from RMA and 771 cells as de-
shows that the identification of major proteasomal scribed (Groettrup et al., 1995). 26-mer peptides (20 mg) were incu-
cleavage sites is feasible and can be highly relevant to bated with 1 mg of purified 20S proteasome at 378C for 24 hr in 300
ml assay buffer as described (Eggers et al., 1995). Digestion productsepitope prediction. Further elucidation and charting of
were separated by RP–HPLC SMART-System equipped with amotifs predicting proteasome cleavage sites can be ex-
mRPC C2/C18 SC 2.1/10 column (Pharmacia) and eluted with apected to improve the accuracy of CTL epitope predic-
gradient of 20%–95% of eluent B (70% acetonitrile in 0.09% TFA)tion from primary amino acid sequences.
in eluent A (0.1% TFA) in 15 min with a flow rate of 50 ml/min, and
analyzed online by a tandem quadrupole mass spectrometer TSQ
Experimental Procedures 7000 (Finnigan MAT) equipped with an electrospray ion source. To
determine the mass of the generated peptides, mass spectra were
Cell Lines/Culture Conditions acquired over the range m/z 300–1300 each 2 s during the HPLC
Tumor cell lines: 771 is an MCF1233-induced B cell lymphoma cell
separation. From these spectra the intensities of all detected ions,line from a C57BL/10 mouse neonatally inoculated with MCF1233
the total ion current, and the intensity of specific peptide ions, theMuLV as described (Sijts etal., 1994a); RBL-5 and RMAare Rauscher
ion current of specific masses, are extracted. The specific peptideMuLV-induced T lymphoma cell lines from C57BL/6 origin (Ljung-
ions detected with intensities three times above background weregren and Ka¨rre, 1985).
sequenced by MS/MS analysis after fragmentation with ArgonCTL clone A9 was isolated from bulk spleen cell culture derived
atoms (2.8 mTorr) using three different collision energies. The pep-from mice immunized with irradiated MCF1233-induced 771 tumor
tide sequence was derived from the masses of the generated frag-cells as described (Sijts et al., 1994a). Spleen cells were restimulated
ment ions. The amount of peptides was determined by the intensitywith the same 771 tumor cells. After 1 week, bulk cultures were
of the ion current of the double or single charged ions after calibra-seeded under limiting dilution conditions and clones were randomly
tion with the synthetic peptides using 10 pmol of an irrelevant pep-isolated and tested for cytotoxicity. Of 12 clones, 3 showed cross-
tide (SYPHFMPTNL) as internal standard. In two experiments, thisreactivity with the FMR analog peptide RSPWFTTL next to reactivity
standard peptide was added to the digest directly before HPLC/MSto the immunodominant epitope KSPWFTTL. Clone A9 was selected
analysis.for further studies. All cells were cultured in Iscove’s modified Dul-
Kinetic study was performed by sampling of 45 ml aliquots frombecco’s medium (GIBCO Biocult, Glascow, United Kingdom) sup-
plemented with 5% fetal calf serum (tumor cells) or 10% fetal calf the digestion mixtures at each timepoint, followed by separation on
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HPLC (eluent A, 0.05% TFA; Eluent B, 70% acetonitrile containing and Kloetzel P. M. (1994). Interferon g stimulation modulates the
proteolytic activity and cleavage site preference of 20S mouse pro-0.05% TFA; gradient, 20%–90% B in 18 min; flow rate, 65 ml/min)
and analyzed online by mass spectrometry. teasomes. J. Exp. Med. 179, 901–909.
Proteasome inhibition studies were done with 1 mg proteasome Ciechanover, A. (1994). The ubiquitin–proteasome proteolytic path-
using 20 mg MCF wild-type peptide in 300 ml assay buffer in the way. Cell 79, 13–21.
presence of 5–50 mM of the aldehyde inhibitors N-acetyl-L-leucinyl- De Campos-Lima, P.O., Levitsky, V., Brooks, J., Lee, S.P., Hu, L.F.,
L-norleucinal (LLnL) (Sigma) or N-carbobenzoxyl-L-leucinyl-L-leuci- Rickinson, A.B., and Masucci, M.G. (1994). T cell responses and
nyl-L-norvalinal (MG-132, similar to MG-115; Rock et al., 1994) (Myo- virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein–
genics,Cambridge, Massachusetts). After 24 hr at 378C, the samples Barr virus isolates from highly A11-positive populations by selective
were subjected to mass spectrometric analysis. The percentage of mutation of anchor residues. J. Exp. Med. 179, 1297–1305.
inhibition was calculated from the intensity of the relevant degrada-
Del Val, M., Schlicht, H.J., Ruppert, T., Reddehase, M.J., and Koszi-tion products (FNKSPWFTTLI and FNKSPWFTTL).
nowski, U.H. (1991). Efficient processing of an antigenic sequence
for its presentation by MHC class I molecules depends on its neigh-TAP Translocation Assays
boring residues in the protein. Cell 66, 1145–1153.TAP-dependent translocation assays were performed as described
Dick, L.R., Aldrich, C., Jameson, S.C., Moomaw, C.R., Pramanik,(Neisig et al., 1995). In short, peptides of interest were tested for
B.C., Doyle, C.K., DeMartino, G.N., Bevan, M.J., Forman, J.M., andtheir ability to compete for TAP-dependent translocation of a 125I-
Slaughter, C.A. (1994). Proteolytic processing of ovalbumin andiodinated model peptide in Streptolysin O-permeabilized RMA cells.
b-galactosidase by the proteasome to yield antigenic peptides. J.
Immunol. 152, 3884–3894.RMA-S MHC Class I Peptide Binding Assay
The RMA-S assay was performed as described previously (Feltkamp Eggers, M., Boes-Fabian, B., Ruppert, T., Kloetzel, P.-M., and Koszi-
et al., 1993). In short, RMA-S cells were cultured for 36 hr at 268C nowski, U.H. (1995). The cleavage preference of the proteasome
and were added to serial dilutions of peptide in serum-free medium. governs the yield of antigenic peptides. J. Exp. Med., AU: in press.
After 4 hr incubation at 378C, cells were washed and incubated with Elliot, T., Willis, A., Cerundolo, V., and Townsend, A. (1995). Pro-
the Kb-specific monoclonal antibody 28.14.8S (Ozato and Sachs, cessing of major histocompatibility class I–restricted antigens in the
1981) for 30 min on ice. After washing, the cells were incubated endoplasmic reticulum. J. Exp. Med. 181, 1481–1491.
with fluorescein isothiocyanate–conjugated goat anti-mouse immu-
Falk, K., Ro¨tzschke, O., Stevanovic, S., Jung, G., and Rammensee,
noglobulin G F(ab9)2 fragments for 30 min on ice and immunofluores- H.-G. (1991). Allele-specific motifs revealed by sequencing of self-
cence was analyzed using a FACScan flow cytometer (Becton Dick-
peptides eluted from MHC molecules. Nature 351, 290–296.
inson, Mountain View, California).
Fehling, H.J., Swat, W., Laplace, C., Ku¨hn, R., Rajewsky, K., Mu¨ller,
U., and von Boehmer, H. (1994). MHC class I expression in miceAcid Elution of Natural Peptides
lacking the proteasome subunit LMP-7. Science 265, 1234–1237.771 and RMA cells (109) were washed with serum-free medium and
Feltkamp, M.C.W., Smits, H.L., Vierboom, M.P.M., Minnaar, R.P., De150 mM NaCl solution to remove serum proteins and buffer. The
Jongh, B.M., Drijfhout, J.W., Ter Schegget, J., Melief, C.J.M., andcells were incubated for 15 min in 0.1% TFA/H2O on ice. Cells were
Kast, W.M. (1993). Vaccination with cytotoxic T lymphocyte epitope-spun down for 15 min at 3000 rpm; the supernatant was collected
containing peptide protects against a tumor induced by humanandsubjected to size exclusion chromatographyto remove proteins.
Papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242–The fractions containing low molecular mass material (<5000 kDa)
2249.were concentrated by solid phase extraction on C18 reversed phase
material. After elution with 50% and 90% acetonitrile, the organic Gausepohl, H., Kraft, M., Boulin, C., and Frank, R.W. (1990) Auto-
solvent was removed by speed Vac concentration to get a final mated multiple peptide synthesis with BOP activation. In Proceed-
volume of 2 ml. HPLC separation was performed as described ings of the Eleventh American Peptide Symposium, J.E. Rivier and
above, collecting 38 fractions of 50 ml each. From each fraction, 1 G. R. Marshall, eds. (ESCOM, Leiden), p. 1003.
ml was diluted in 50 ml medium and tested in triplicate in a cytotoxic- Goldberg, A.L., and Rock, K.L. (1992). Proteolysis, proteasomes and
ity assay. 51Cr-labeled RBL-5 target cells were added in 50 ml and antigen presentation. Nature 357, 9–23.
after 1 hr preincubation CTL clone A9 was added (E:T 5 5) and
Groettrup, M., Ruppert, T., Kuehn, L., Seeger, M., Standera, S.,incubated for 5 hr.
Koszinowski, U., Kloetzel, P.-M. (1995). The interferon-g inducibleA coelution experiment was performed using the same HPLC
11S regulator (PA28) and the LMP2/LMP7 subunits govern the pep-conditions to separate synthetic peptides to determine the fraction
tide production by the 20S proteasome in vitro. J. Biol. Chem. 270,at which the individual length variants elute.
23808–23815.
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